Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsCancer

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223494

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223494

NA Uterine Cancer Diagnostics Market - Industry Trends and Forecast to 2030

PUBLISHED:
PAGES: 320 Pages
DELIVERY TIME: Inquiry
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 3500
PDF (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

Description

Table of Contents

List of Tables

North America uterine cancer diagnostics market is projected to register a CAGR of 11.2% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

North America Uterine Cancer Diagnostics Market, By Diagnostic Type (Instrument Based and Procedure Based), Type (Endometrial Cancer and Uterine Sarcoma), Age Group (<30, 31-40, 41-50, 51-60 And >60), End User (Hospitals, Diagnostic Centres, Cancer Research Centre, Ambulatory Surgical Centres, Specialized Clinics, and Others), Distribution Channel (Direct Tender, Third Party Distributors, and Others), Country (U.S., Canada, and Mexico) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Global uterine cancer diagnostics market are:

Increasing uterine cancer patients among the women population

Rise in technological advancement for uterine cancer diagnostic

Market Players

The key market players operating in the North America uterine cancer diagnostics market are:

F-Hoffmann La Roche Ltd.

Siemens Healthcare Private Limited

ESAOTE SPA

Narang Medical Limited

Olympus Corporation

Integra LifeSciences

KARL STORZ SE & Co. KG

Stryker

General Electric Company

FUJIFILM Corporation

Koninklijke Philips N.V.

B. Braun SE

AED.MD

GRAIL

Show more

TABLE OF CONTENTS

1 INTRODUCTION 117

  • 1.1 OBJECTIVES OF THE STUDY 117
  • 1.2 MARKET DEFINITION 117
  • 1.3 OVERVIEW OF THE NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET 117
  • 1.4 CURRENCY AND PRICING 119
  • 1.5 LIMITATIONS 119
  • 1.6 MARKETS COVERED 119

2 MARKET SEGMENTATION 127

  • 2.1 MARKETS COVERED 127
  • 2.2 GEOGRAPHICAL SCOPE 128
  • 2.3 YEARS CONSIDERED FOR THE STUDY 129
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 130
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 133
  • 2.6 MULTIVARIATE MODELLING 134
  • 2.7 MARKET APPLICATION COVERAGE GRID 135
  • 2.8 INSTRUMENT BASED LIFELINE CURVE 136
  • 2.9 DBMR MARKET POSITION GRID 137
  • 2.10 VENDOR SHARE ANALYSIS 139
  • 2.11 SECONDARY SOURCES 140
  • 2.12 ASSUMPTIONS 140

3 EXECUTIVE SUMMARY 141

4 PREMIUM INSIGHTS 144

  • 4.1 PESTEL ANALYSIS 145
  • 4.2 PORTER'S FIVE FORCES 146
  • 4.3 PATENT ANALYSIS OF NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET 147
  • 4.4 REIMBURSEMENT SCENARIO 148
  • 4.5 INDUSTRY INSIGHTS: 149
  • 4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 149
  • 4.7 PRICING STRATEGIES 149
  • 4.8 CONCLUSION 150
  • 4.9 PREVALENCE, INCIDENCE, AND MORTALITY RATE OF UTERINE CANCER 151
  • 4.10 COST OF UTERINE CANCER PROCEDURE 153

5 REGULATORY FRAMEWORK 154

6 MARKET OVERVIEW 156

  • 6.1 DRIVERS 158
    • 6.1.1 TECHNOLOGICAL ADVANCEMENTS IN UTERINE CANCER DIAGNOSTICS 158
    • 6.1.2 RISING DEMAND FOR MINIMALLY INVASIVE ADVANCED SCREENING TECHNIQUES 158
    • 6.1.3 RISING AWARENESS TOWARDS UTERINE CANCER 159
    • 6.1.4 RISING IMPORTANCE OF WOMEN'S HEALTH 159
  • 6.2 RESTRAINTS 160
    • 6.2.1 HIGH RISK COMPLICATIONS DURING DIAGNOSTIC TESTS 160
    • 6.2.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF UTERINE CANCER 160
  • 6.3 OPPORTUNITIES 161
    • 6.3.1 INCREASING PREVALENCE OF UTERINE CANCER 161
    • 6.3.2 RISE IN ADOPTION OF SEDENTARY LIFESTYLE 161
    • 6.3.3 GROWTH IN MENSTRUAL COMPLICATIONS 162
  • 6.4 CHALLENGES 162
    • 6.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 162
    • 6.4.2 HIGH COST OF IMAGING SYSTEMS 163

7 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE 164

  • 7.1 OVERVIEW 165
  • 7.2 INSTRUMENT-BASED 168
    • 7.2.1 ULTRASOUND SCANNING 169
      • 7.2.1.1 SYSTEMS 169
      • 7.2.1.2 ABDOMINAL ULTRASOUND SCANNING 170
      • 7.2.1.3 TRANSVAGINAL ULTRASOUND SCANNING 170
      • 7.2.1.4 ACCESSORIES 170
    • 7.2.2 IMAGING DEVICES 170
      • 7.2.2.1 CT/PET (POSITRON EMISSION TOMOGRAPHY) SCAN 171
      • 7.2.2.2 MAGNETIC RESONANCE IMAGING (MRI) 171
      • 7.2.2.3 COMPUTED TOMOGRAPHY (CT) SCAN 171
      • 7.2.2.4 OTHERS 171
    • 7.2.3 TESTS 172
      • 7.2.3.1 BLOOD TESTS 172
        • 7.2.3.1.1 COMPLETE BLOOD COUNT 172
        • 7.2.3.1.2 CA125 MARKER BLOOD TEST 172
      • 7.2.3.2 URINE TESTS 173
      • 7.2.3.3 OTHER TESTS 173
    • 7.2.4 OTHERS 173
  • 7.3 PROCEDURE BASED 173
    • 7.3.1 ENDOMETRIAL BIOPSY 174
    • 7.3.2 HYSTEROSCOPY 174
    • 7.3.3 DILATION & CURETTAGE 174
    • 7.3.4 CYSTOSCOPY 174
    • 7.3.5 PROCTOSCOPY 175
    • 7.3.6 OTHERS 175

8 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE 176

  • 8.1 OVERVIEW 177
  • 8.2 ENDOMETRIAL CANCER 180
    • 8.2.1 SEROUS ADENOCARCINOMA 181
      • 8.2.1.1 INSTRUMENT-BASED 181
        • 8.2.1.1.1 ULTRASOUND SCANNING 182
        • 8.2.1.1.2 IMAGING DEVICES 182
        • 8.2.1.1.3 TESTS 182
        • 8.2.1.1.4 OTHERS 182
      • 8.2.1.2 PROCEDURE-BASED 183
        • 8.2.1.2.1 ENDOMETRIAL BIOPSY 183
        • 8.2.1.2.2 HYSTEROSCOPY 183
        • 8.2.1.2.3 DILATION & CURETTAGE 183
        • 8.2.1.2.4 CYSTOSCOPY 183
        • 8.2.1.2.5 PROCTOSCOPY 183
        • 8.2.1.2.6 OTHERS 184
    • 8.2.2 ADENOSQUAMOUS CARCINOMA 184
      • 8.2.2.1 INSTRUMENT-BASED 184
        • 8.2.2.1.1 ULTRASOUND SCANNING 184
        • 8.2.2.1.2 IMAGING DEVICES 185
        • 8.2.2.1.3 TESTS 185
        • 8.2.2.1.4 OTHERS 185
      • 8.2.2.2 PROCEDURE-BASED 185
        • 8.2.2.2.1 ENDOMETRIAL BIOPSY 185
        • 8.2.2.2.2 HYSTEROSCOPY 185
        • 8.2.2.2.3 DILATION & CURETTAGE 186
        • 8.2.2.2.4 CYSTOSCOPY 186
        • 8.2.2.2.5 PROCTOSCOPY 186
        • 8.2.2.2.6 OTHERS 186
    • 8.2.3 UTERINE CARCINOSARCOMA 186
      • 8.2.3.1 INSTRUMENT-BASED 186
        • 8.2.3.1.1 ULTRASOUND SCANNING 187
        • 8.2.3.1.2 IMAGING DEVICES 187
        • 8.2.3.1.3 TESTS 187
        • 8.2.3.1.4 OTHERS 187
      • 8.2.3.2 PROCEDURE-BASED 188
        • 8.2.3.2.1 ENDOMETRIAL BIOPSY 188
        • 8.2.3.2.2 HYSTEROSCOPY 188
        • 8.2.3.2.3 DILATION & CURETTAGE 188
        • 8.2.3.2.4 CYSTOSCOPY 188
        • 8.2.3.2.5 PROCTOSCOPY 188
        • 8.2.3.2.6 OTHERS 189
    • 8.2.4 PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM 189
      • 8.2.4.1 INSTRUMENT-BASED 189
        • 8.2.4.1.1 ULTRASOUND SCANNING 189
        • 8.2.4.1.2 IMAGING DEVICES 190
        • 8.2.4.1.3 TESTS 190
        • 8.2.4.1.4 OTHERS 190
      • 8.2.4.2 PROCEDURE-BASED 190
        • 8.2.4.2.1 ENDOMETRIAL BIOPSY 190
        • 8.2.4.2.2 HYSTEROSCOPY 190
        • 8.2.4.2.3 DILATION & CURETTAGE 191
        • 8.2.4.2.4 CYSTOSCOPY 191
        • 8.2.4.2.5 PROCTOSCOPY 191
        • 8.2.4.2.6 OTHERS 191
  • 8.3 UTERINE SARCOMA 191
    • 8.3.1 LEIOMYOSARCOMA 192
      • 8.3.1.1 INSTRUMENT-BASED 192
        • 8.3.1.1.1 ULTRASOUND SCANNING 193
        • 8.3.1.1.2 IMAGING DEVICES 193
        • 8.3.1.1.3 TESTS 193
        • 8.3.1.1.4 OTHERS 193
      • 8.3.1.2 PROCEDURE-BASED 194
        • 8.3.1.2.1 ENDOMETRIAL BIOPSY 194
        • 8.3.1.2.2 HYSTEROSCOPY 194
        • 8.3.1.2.3 DILATION & CURETTAGE 194
        • 8.3.1.2.4 CYSTOSCOPY 194
        • 8.3.1.2.5 PROCTOSCOPY 194
        • 8.3.1.2.6 OTHERS 195
    • 8.3.2 ENDOMETRIAL STROMAL SARCOMA 195
      • 8.3.2.1 INSTRUMENT-BASED 195
        • 8.3.2.1.1 ULTRASOUND SCANNING 195
        • 8.3.2.1.2 IMAGING DEVICES 196
        • 8.3.2.1.3 TESTS 196
        • 8.3.2.1.4 OTHERS 196
      • 8.3.2.2 PROCEDURE-BASED 196
        • 8.3.2.2.1 ENDOMETRIAL BIOPSY 196
        • 8.3.2.2.2 HYSTEROSCOPY 196
        • 8.3.2.2.3 DILATION & CURETTAGE 197
        • 8.3.2.2.4 CYSTOSCOPY 197
        • 8.3.2.2.5 PROCTOSCOPY 197
        • 8.3.2.2.6 OTHERS 197
    • 8.3.3 UNDIFFERENTIATED SARCOMA 197
      • 8.3.3.1 INSTRUMENT-BASED 198
        • 8.3.3.1.1 ULTRASOUND SCANNING 198
        • 8.3.3.1.2 IMAGING DEVICES 198
        • 8.3.3.1.3 TESTS 198
        • 8.3.3.1.4 OTHERS 198
      • 8.3.3.2 PROCEDURE-BASED 199
        • 8.3.3.2.1 ENDOMETRIAL BIOPSY 199
        • 8.3.3.2.2 HYSTEROSCOPY 199
        • 8.3.3.2.3 DILATION & CURETTAGE 199
        • 8.3.3.2.4 CYSTOSCOPY 199
        • 8.3.3.2.5 PROCTOSCOPY 200
        • 8.3.3.2.6 OTHERS 200

9 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP 201

  • 9.1 OVERVIEW 202
  • 9.2 >60 YEARS 205
  • 9.3 51-60 YEARS 206
  • 9.4 41-50 YEARS 207
  • 9.5 31-40 YEARS 208
  • 9.6 <30 YEARS 209

10 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY END USER 210

  • 10.1 OVERVIEW 211
  • 10.2 HOSPITALS 214
  • 10.3 DIAGNOSTIC CENTERS 215
  • 10.4 CANCER RESEARCH CENTERS 216
  • 10.5 AMBULATORY SURGICAL CENTERS 217
  • 10.6 SPECIALIZED CLINICS 218
  • 10.7 OTHERS 219

11 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 220

  • 11.1 OVERVIEW 221
  • 11.2 DIRECT TENDER 224
  • 11.3 THIRD PARTY DISTRIBUTORS 225
  • 11.4 OTHERS 226

12 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY REGION 227

  • 12.1 NORTH AMERICA 228
    • 12.1.1 U.S. 244
    • 12.1.2 CANADA 255
    • 12.1.3 MEXICO 266

13 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 279

  • 13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 279

14 SWOT ANALYSIS 280

15 COMPANY PROFILE 281

  • 15.1 KONINKLIJKE PHILIPS N.V. 281
    • 15.1.1 COMPANY SNAPSHOT 281
    • 15.1.2 REVENUE ANALYSIS 281
    • 15.1.3 COMPANY SHARE ANALYSIS 282
    • 15.1.4 PRODUCT PORTFOLIO 282
    • 15.1.5 RECENT DEVELOPMENTS 282
  • 15.2 CANON MEDICAL SYSTEMS ANZ PTY LIMITED. 284
    • 15.2.1 COMPANY SNAPSHOT 284
    • 15.2.2 COMPANY SHARE ANALYSIS 284
    • 15.2.3 PRODUCT PORTFOLIO 285
    • 15.2.4 RECENT DEVELOPMENTS 285
  • 15.3 GENERAL ELECTRIC COMPANY 286
    • 15.3.1 COMPANY SNAPSHOT 286
    • 15.3.2 REVENUE ANALYSIS 286
    • 15.3.3 COMPANY SHARE ANALYSIS 287
    • 15.3.4 PRODUCT PORTFOLIO 287
    • 15.3.5 RECENT DEVELOPMENTS 287
  • 15.4 SIEMENS HEALTHCARE GMBH 289
    • 15.4.1 COMPANY SNAPSHOT 289
    • 15.4.2 REVENUE ANALYSIS 289
    • 15.4.3 COMPANY SHARE ANALYSIS 290
    • 15.4.4 PRODUCT PORTFOLIO 290
    • 15.4.5 RECENT DEVELOPMENTS 290
  • 15.5 FUJIFILM CORPORATION 291
    • 15.5.1 COMPANY SNAPSHOT 291
    • 15.5.2 REVENUE ANALYSIS 291
    • 15.5.3 COMPANY SHARE ANALYSIS 292
    • 15.5.4 PRODUCT PORTFOLIO 292
    • 15.5.5 RECENT DEVELOPMENTS 292
  • 15.6 AED.MD 294
    • 15.6.1 COMPANY SNAPSHOT 294
    • 15.6.2 PRODUCT PORTFOLIO 294
    • 15.6.3 RECENT DEVELOPMENTS 294
  • 15.7 ARQUER DIAGNOSTICS LTD 295
    • 15.7.1 COMPANY SNAPSHOT 295
    • 15.7.2 PRODUCT PORTFOLIO 295
    • 15.7.3 RECENT DEVELOPMENTS 295
  • 15.8 B. BRAUN SE 296
    • 15.8.1 COMPANY SNAPSHOT 296
    • 15.8.2 PRODUCT PORTFOLIO 296
    • 15.8.3 RECENT DEVELOPMENTS 296
  • 15.9 ESAOTE SPA 297
    • 15.9.1 COMPANY SNAPSHOT 297
    • 15.9.2 PRODUCT PORTFOLIO 297
    • 15.9.3 RECENT DEVELOPMENTS 297
  • 15.10 F. HOFFMANN-LA ROCHE LTD 299
    • 15.10.1 COMPANY SNAPSHOT 299
    • 15.10.2 REVENUE ANALYSIS 299
    • 15.10.3 PRODUCT PORTFOLIO 300
    • 15.10.4 RECENT DEVELOPMENTS 300
Show more
  • 15.11 GRAIL 301
    • 15.11.1 COMPANY SNAPSHOT 301
    • 15.11.2 PRODUCT PORTFOLIO 301
    • 15.11.3 RECENT DEVELOPMENTS 301
  • 15.12 GUZIP BIOMARKERS CORPORATION 303
    • 15.12.1 COMPANY SNAPSHOT 303
    • 15.12.2 PRODUCT PORTFOLIO 303
    • 15.12.3 RECENT DEVELOPMENTS 303
  • 15.13 INTEGRA LIFESCIENCES 304
    • 15.13.1 COMPANY SNAPSHOT 304
    • 15.13.2 REVENUE ANALYSIS 304
    • 15.13.3 PRODUCT PORTFOLIO 305
    • 15.13.4 RECENT DEVELOPMENTS 305
  • 15.14 JALAL SURGICAL 306
    • 15.14.1 COMPANY SNAPSHOT 306
    • 15.14.2 PRODUCT PORTFOLIO 306
    • 15.14.3 RECENT DEVELOPMENTS 306
  • 15.15 KARL STORZ SE & CO. KG 307
    • 15.15.1 COMPANY SNAPSHOT 307
    • 15.15.2 PRODUCT PORTFOLIO 307
    • 15.15.3 RECENT DEVELOPMENTS 308
  • 15.16 MEDTRONIC 309
    • 15.16.1 COMPANY SNAPSHOT 309
    • 15.16.2 REVENUE ANALYSIS 309
    • 15.16.3 PRODUCT PORTFOLIO 310
    • 15.16.4 RECENT DEVELOPMENTS 310
  • 15.17 NARANG MEDICAL LIMITED 311
    • 15.17.1 COMPANY SNAPSHOT 311
    • 15.17.2 PRODUCT PORTFOLIO 311
    • 15.17.3 RECENT DEVELOPMENTS 311
  • 15.18 OLYMPUS CORPORATION 312
    • 15.18.1 COMPANY SNAPSHOT 312
    • 15.18.2 REVENUE ANALYSIS 312
    • 15.18.3 PRODUCT PORTFOLIO 313
    • 15.18.4 RECENT DEVELOPMENTS 313
  • 15.19 STRYKER 314
    • 15.19.1 COMPANY SNAPSHOT 314
    • 15.19.2 REVENUE ANALYSIS 314
    • 15.19.3 PRODUCT PORTFOLIO 315
    • 15.19.4 RECENT DEVELOPMENTS 315
  • 15.20 SURTEX INSTRUMENTS LIMITED. 316
    • 15.20.1 COMPANY SNAPSHOT 316
    • 15.20.2 PRODUCT PORTFOLIO 316
    • 15.20.3 RECENT DEVELOPMENTS 316

16 QUESTIONNAIRE 317

17 RELATED REPORTS 320

LIST OF TABLES

  • TABLE 1 NORTH AMERICA RATE OF ENDOMETRIAL CANCER (2020) 60
  • TABLE 2 U.S. (2022) 60
  • TABLE 3 U.K. (2019) 60
  • TABLE 4 GERMANY RATE OF ENDOMETRIAL CANCER (2019) 60
  • TABLE 5 POLAND RATE OF ENDOMETRIAL CANCER (2020) 60
  • TABLE 6 SINGAPORE (2020) 60
  • TABLE 7 JAPAN (2022) 60
  • TABLE 8 INDIA (2020) 61
  • TABLE 9 AUSTRALIA (2022) 61
  • TABLE 10 BRAZIL RATE OF ENDOMETRIAL CANCER (2018) 61
  • TABLE 11 ARGENTINA (2020) 61
  • TABLE 12 UAE (2020) 61
  • TABLE 13 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 76
  • TABLE 14 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 77
  • TABLE 15 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 77
  • TABLE 16 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 78
  • TABLE 17 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 78
  • TABLE 18 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 78
  • TABLE 19 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 79
  • TABLE 20 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 79
  • TABLE 21 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 80
  • TABLE 22 NORTH AMERICA TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 81
  • TABLE 23 NORTH AMERICA BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 81
  • TABLE 24 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
  • TABLE 25 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 83
  • TABLE 26 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 83
  • TABLE 27 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 88
  • TABLE 28 NORTH AMERICA ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
  • TABLE 29 NORTH AMERICA ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 90
  • TABLE 30 NORTH AMERICA SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 90
  • TABLE 31 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 91
  • TABLE 32 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 92
  • TABLE 33 NORTH AMERICA ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 93
  • TABLE 34 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 93
  • TABLE 35 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 94
  • TABLE 36 NORTH AMERICA UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 95
  • TABLE 37 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 96
  • TABLE 38 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 97
  • TABLE 39 NORTH AMERICA PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 98
  • TABLE 40 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 98
  • TABLE 41 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 99
  • TABLE 42 NORTH AMERICA UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 100
  • TABLE 43 NORTH AMERICA UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 101
  • TABLE 44 NORTH AMERICA LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 101
  • TABLE 45 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 102
  • TABLE 46 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 103
  • TABLE 47 NORTH AMERICA ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 104
  • TABLE 48 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 104
  • TABLE 49 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 105
  • TABLE 50 NORTH AMERICA UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 106
  • TABLE 51 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 107
  • TABLE 52 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 108
  • TABLE 53 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 113
  • TABLE 54 NORTH AMERICA >60 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 114
  • TABLE 55 NORTH AMERICA 51-60 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 115
  • TABLE 56 NORTH AMERICA 41-50 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 116
  • TABLE 57 NORTH AMERICA 31-40 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 117
  • TABLE 58 NORTH AMERICA <30 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 118
  • TABLE 59 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 122
  • TABLE 60 NORTH AMERICA HOSPITALS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 123
  • TABLE 61 NORTH AMERICA DIAGNOSTIC CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 124
  • TABLE 62 NORTH AMERICA CANCER RESEARCH CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 125
  • TABLE 63 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 126
  • TABLE 64 NORTH AMERICA SPECIALIZED CLINICS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 127
  • TABLE 65 NORTH AMERICA OTHERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 128
  • TABLE 66 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 132
  • TABLE 67 NORTH AMERICA DIRECT TENDER IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 133
  • TABLE 68 NORTH AMERICA THIRD PARTY DISTRIBUTORS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 134
  • TABLE 69 NORTH AMERICA OTHERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 135
  • TABLE 70 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 141
  • TABLE 71 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 141
  • TABLE 72 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 141
  • TABLE 73 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 141
  • TABLE 74 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 142
  • TABLE 75 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 142
  • TABLE 76 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 142
  • TABLE 77 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME) 142
  • TABLE 78 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 142
  • TABLE 79 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 143
  • TABLE 80 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 143
  • TABLE 81 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 143
  • TABLE 82 NORTH AMERICA TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 143
  • TABLE 83 NORTH AMERICA BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 144
  • TABLE 84 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 144
  • TABLE 85 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME) 144
  • TABLE 86 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 145
  • TABLE 87 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 145
  • TABLE 88 NORTH AMERICA ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 145
  • TABLE 89 NORTH AMERICA SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 145
  • TABLE 90 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 146
  • TABLE 91 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 146
  • TABLE 92 NORTH AMERICA ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 146
  • TABLE 93 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 146
  • TABLE 94 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 147
  • TABLE 95 NORTH AMERICA UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 147
  • TABLE 96 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 147
  • TABLE 97 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 148
  • TABLE 98 NORTH AMERICA PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 148
  • TABLE 99 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 148
  • TABLE 100 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 149
  • TABLE 101 NORTH AMERICA UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 149
  • TABLE 102 NORTH AMERICA LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 149
  • TABLE 103 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 149
  • TABLE 104 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 150
  • TABLE 105 NORTH AMERICA ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 150
  • TABLE 106 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 150
  • TABLE 107 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 150
  • TABLE 108 NORTH AMERICA UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 151
  • TABLE 109 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 151
  • TABLE 110 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 151
  • TABLE 111 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 151
  • TABLE 112 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 152
  • TABLE 113 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 152
  • TABLE 114 U.S. UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 153
  • TABLE 115 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 153
  • TABLE 116 U.S. ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 153
  • TABLE 117 U.S. ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 153
  • TABLE 118 U.S. ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 154
  • TABLE 119 U.S. SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 154
  • TABLE 120 U.S. SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME) 154
  • TABLE 121 U.S. SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 154
  • TABLE 122 U.S. IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 154
  • TABLE 123 U.S. IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS) 155
  • TABLE 124 U.S. IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 155
  • TABLE 125 U.S. TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 155
  • TABLE 126 U.S. BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 155
  • TABLE 127 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 156
  • TABLE 128 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME) 156
  • TABLE 129 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD) 156
  • TABLE 130 U.S. UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 156
  • TABLE 131 U.S. ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 157
  • TABLE 132 U.S. SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 157
  • TABLE 133 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 157
  • TABLE 134 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 158
  • TABLE 135 U.S. ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 158
  • TABLE 136 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 158
  • TABLE 137 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 158
  • TABLE 138 U.S. UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 159
  • TABLE 139 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 159
  • TABLE 140 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 159
  • TABLE 141 U.S. PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 160
  • TABLE 142 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 160
  • TABLE 143 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION) 160

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: SEGMENTATION 35
  • FIGURE 2 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION 38
  • FIGURE 3 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: DROC ANALYSIS 39
  • FIGURE 4 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 40
  • FIGURE 5 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 40
  • FIGURE 6 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 41
  • FIGURE 7 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: MARKET APPLICATION COVERAGE GRID 43
  • FIGURE 8 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID 45
  • FIGURE 9 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 47
  • FIGURE 10 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: SEGMENTATION 51
  • FIGURE 11 GROWING AWARENESS OF UTERINE CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 52
  • FIGURE 12 INSTRUMENT BASED SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET IN 2023 & 2030 52
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE UTERINE CANCER DIAGNOSTICS MARKET 65
  • FIGURE 14 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, 2022 73
  • FIGURE 15 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, 2023-2030 (USD MILLION) 74
  • FIGURE 16 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, CAGR (2023-2030) 74
  • FIGURE 17 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, LIFELINE CURVE 75
  • FIGURE 18 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, 2022 85
  • FIGURE 19 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, 2023-2030 (USD MILLION) 86
  • FIGURE 20 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, CAGR (2023-2030) 86
  • FIGURE 21 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, LIFELINE CURVE 87
  • FIGURE 22 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022 110
  • FIGURE 23 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 111
  • FIGURE 24 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030) 111
  • FIGURE 25 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE 112
  • FIGURE 26 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, 2022 119
  • FIGURE 27 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION) 120
  • FIGURE 28 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030) 120
  • FIGURE 29 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE 121
  • FIGURE 30 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022 129
  • FIGURE 31 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 130
  • FIGURE 32 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 130
  • FIGURE 33 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE 131
  • FIGURE 34 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 137
  • FIGURE 35 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 138
  • FIGURE 36 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 138
  • FIGURE 37 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 139
  • FIGURE 38 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE (2023-2030) 139
  • FIGURE 39 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 187
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!